Čes. slov. farm. 2022, 71(3):116-120 | DOI: 10.5817/CSF2022-3-116

Study of possible sex features of ramipril and candesartan treatment under experimental arterial hypertension in rats

Natalia Tsubanova¹, Alona Kovpak^2,*, Igor Zamorskyi²

¹ National University of Pharmacy, Kharkiv, Ukraine

² Bukovinian State Medical University, Chernivtsi, Ukraine

The article presents the results of a preclinical study of ramipril and candesartan in an experimental group of hypertensive rats of different sexes. Antihypertensive therapy was performed for 21 days. The drugs were administered daily in moderate therapeutic doses calculated for rats using the coefficient of species sensitivity. It was found that the course of experimental hypertension has gender differences, and in males, according to blood pressure, the level of NO metabolites is more pronounced. The use of ramipril from the group of ACE inhibitors and candesartan from the ARBs group in experimental hypertension in rats has gender differences. Ramipril is likely to be more effective in normalizing blood pressure and endothelial function in males than females. The use of candesartan did not show significant gender differences, but there was a tendency for females to be slightly more effective than males. Established gender differences in hypertension pharmacotherapy should be considered to optimize treatment.

Keywords: hypertension; gender differences; ramipril; candesartan

Received: February 18, 2022; Accepted: April 27, 2022; Published: March 1, 2022  Show citation